Fiduciary Trust’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.32M | Sell |
69,163
-20,792
| -23% | -$893K | 0.04% | 216 |
|
|
2026
Q1 | $3.31M | Sell |
89,955
-14,520
| -14% | -$688K | 0.04% | 217 |
|
|
2025
Q4 | $5.32M | Sell |
104,475
-18,840
| -15% | -$963K | 0.06% | 163 |
|
|
2025
Q3 | $6.84M | Sell |
123,315
-19,572
| -14% | -$1.15M | 0.08% | 143 |
|
|
2025
Q2 | $9.86M | Sell |
142,887
-24,308
| -15% | -$1.65M | 0.12% | 105 |
|
|
2025
Q1 | $11.6M | Sell |
167,195
-30,371
| -15% | -$2.51M | 0.15% | 97 |
|
|
2024
Q4 | $17M | Sell |
197,566
-1,113
| -0.6% | -$120K | 0.22% | 68 |
|
|
2024
Q3 | $23.7M | Sell |
198,679
-2,595
| -1% | -$346K | 0.33% | 56 |
|
|
2024
Q2 | $28.7M | Sell |
201,274
-6,420
| -3% | -$851K | 0.43% | 44 |
|
|
2024
Q1 | $26.7M | Sell |
207,694
-1,930
| -0.9% | -$230K | 0.41% | 50 |
|
|
2023
Q4 | $21.7M | Sell |
209,624
-1,480
| -0.7% | -$146K | 0.36% | 52 |
|
|
2023
Q3 | $19.2M | Sell |
211,104
-3,098
| -1% | -$273K | 0.35% | 53 |
|
|
2023
Q2 | $17.3M | Sell |
214,202
-2,224
| -1% | -$182K | 0.31% | 60 |
|
|
2023
Q1 | $17.2M | Sell |
216,426
-942
| -0.4% | -$66.8K | 0.32% | 59 |
|
|
2022
Q4 | $14.7M | Sell |
217,368
-1,476
| -0.7% | -$86.5K | 0.29% | 67 |
|
|
2022
Q3 | $10.9M | Sell |
218,844
-2,040
| -0.9% | -$109K | 0.24% | 75 |
|
|
2022
Q2 | $12.3M | Sell |
220,884
-4,594
| -2% | -$255K | 0.26% | 77 |
|
|
2022
Q1 | $12.5M | Sell |
225,478
-776
| -0.3% | -$39.8K | 0.22% | 86 |
|
|
2021
Q4 | $12.7M | Sell |
226,254
-2,038
| -0.9% | -$110K | 0.21% | 94 |
|
|
2021
Q3 | $11M | Sell |
228,292
-12,194
| -5% | -$590K | 0.2% | 99 |
|
|
2021
Q2 | $10.1M | Sell |
240,486
-40,694
| -14% | -$1.58M | 0.19% | 104 |
|
|
2021
Q1 | $9.48M | Sell |
281,180
-6,320
| -2% | -$225K | 0.19% | 99 |
|
|
2020
Q4 | $10M | Sell |
287,500
-18,688
| -6% | -$646K | 0.21% | 97 |
|
|
2020
Q3 | $10.6M | Sell |
306,188
-2,990
| -1% | -$99.7K | 0.25% | 78 |
|
|
2020
Q2 | $10.1M | Sell |
309,178
-4,754
| -2% | -$152K | 0.25% | 80 |
|
|
2020
Q1 | $9.45M | Sell |
313,932
-120
| -0% | -$3.57K | 0.27% | 78 |
|
|
2019
Q4 | $9.09M | Sell |
314,052
-5,250
| -2% | -$145K | 0.21% | 95 |
|
|
2019
Q3 | $8.25M | Sell |
319,302
-12,906
| -4% | -$326K | 0.21% | 99 |
|
|
2019
Q2 | $8.48M | Sell |
332,208
-5,536
| -2% | -$137K | 0.22% | 91 |
|
|
2019
Q1 | $8.83M | Sell |
337,744
-6,488
| -2% | -$159K | 0.24% | 88 |
|
|
2018
Q4 | $7.93M | Sell |
344,232
-4,040
| -1% | -$89.8K | 0.24% | 86 |
|
|
2018
Q3 | $8.21M | Sell |
348,272
-3,900
| -1% | -$95.2K | 0.23% | 95 |
|
|
2018
Q2 | $8.12M | Sell |
352,172
-4,300
| -1% | -$102K | 0.25% | 93 |
|
|
2018
Q1 | $8.78M | Sell |
356,472
-8,350
| -2% | -$219K | 0.27% | 91 |
|
|
2017
Q4 | $9.79M | Sell |
364,822
-4,012
| -1% | -$102K | 0.29% | 88 |
|
|
2017
Q3 | $8.88M | Sell |
368,834
-11,500
| -3% | -$260K | 0.27% | 90 |
|
|
2017
Q2 | $8.16M | Sell |
380,334
-39,098
| -9% | -$789K | 0.25% | 94 |
|
|
2017
Q1 | $7.19M | Sell |
419,432
-87,598
| -17% | -$1.53M | 0.22% | 97 |
|
|
2016
Q4 | $9.09M | Sell |
507,030
-103,548
| -17% | -$1.88M | 0.29% | 86 |
|
|
2016
Q3 | $12.7M | Sell |
610,578
-6,926
| -1% | -$172K | 0.43% | 67 |
|
|
2016
Q2 | $16.6M | Sell |
617,504
-54,154
| -8% | -$1.49M | 0.58% | 50 |
|
|
2016
Q1 | $18.2M | Buy |
+671,658
| New | +$18M | 0.64% | 45 |
|
Other funds holding NVO
F
Fiduciary Trust's NVO Position: Q2 2026 in Review
Fiduciary Trust reduced its Novo Nordisk (NVO) stake by 23% in Q2 2026, selling an estimated $893K and leaving 69,163 shares worth $3.32M. The position accounts for 0.04% of the portfolio, ranked #216.
Fiduciary Trust first reported a position in NVO in Q1 2016 and has held it in 42 quarters since. The position peaked at $28.7M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Fiduciary Trust held 69,163 shares of Novo Nordisk worth $3.32M as of Q2 2026.
- Fiduciary Trust sold 20,792 Novo Nordisk shares in Q2 2026, an estimated $893K.
- Novo Nordisk made up 0.04% of Fiduciary Trust's portfolio in Q2 2026, its #216 holding.
- Fiduciary Trust first reported a position in Novo Nordisk in Q1 2016 and has held it in 42 quarters since.
- Fiduciary Trust's Novo Nordisk position peaked at $28.7M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.